As a proof-of-concept, CPP-PMOs were first evaluated for their ability to increase MBNL1 levels (i.e., the expected activity of the antimiR) in a DM1 cell model developed by Arandel et al.38 Here, MBNL1 is linked to myotonic dystrophy type 1.